This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Oragenics’s 8K filing here.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
- Five stocks we like better than Oragenics
- What is the Euro STOXX 50 Index?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- How to Most Effectively Use the MarketBeat Earnings Screener
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Conference Calls and Individual Investors
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
